Best 3 Blue Chip Stocks to Buy After the Market's Pullback

S&P 500 is ~5% below its all-time high amid geopolitical (Iran) and market volatility; author recommends defensive blue-chip buys. American Express Q4 revenue $17.18B (+10% YoY) and net income $2.46B (+13% YoY); strong new-account growth from Millennials/Gen Z (65% of new accounts in 2025; avg ages 33 and 29) and a 1.3% dividend yield. UnitedHealth full-year 2025 revenue $447.6B (+12% YoY) with earnings $19B (-41% YoY); shares are down ~46% over 12 months but company projects 2026 EPS > $17.75 (vs $16.35 in 2025) and yields ~3.2%. Enterprise Products Partners Q4 revenue $13.79B (vs $14.2B prior), net income $1.64B (vs $1.62B) and EPS $0.75; it offers a 5.8% dividend yield and benefits from midstream stability amid oil/gas focus.

Analysis

American Express’s younger, affluent cohort is a structural positive but not a free option — it compresses the time-to-payback on expensive rewards and referral-driven CAC and shifts the firm’s exposure toward longer-term unsecured receivables and higher volatility of spend-per-customer. That amplifies sensitivity to wage and gig-economy cycles: modest weakness in real wages or a tightening in unsecured credit standards could disproportionately dent AmEx’s forward ROIC even if new-account growth remains robust.

UnitedHealth’s recent mispricing episode is the kind of forced re-underwriting that cascades: expect competitors to re-score MA bids, tighten provider contracts, and reduce upside in ancillary PBM rebates for 2-4 quarters while rate-setting and audits play out — a multi-quarter headwind to margin recovery even if top-line membership stays stable. This also raises political/regulatory path risk: CMS adjustments or retrospective settlements become higher-probability catalysts that can erase any valuation multiple rerating.

Enterprise’s midstream cash flows are the cleanest macro hedge here — fee-based tolling and long-dated contracts dampen commodity-driven EBITDA swings, but regional takeaway constraints and changing export routes (sanctions/insurance costs from geopolitical shocks) can concentrate basis-driven upside or downside in specific assets. Structurally, investors get asymmetric outcomes: modest oil/gas volatility buys elevated immediate distributable cash, while sustained secular declines in US hydrocarbon production or accelerated electrification would compress growth optionality over years rather than months.

Key Decisions for Investors

• AXP — Tactical accumulation on weakness: scale into a 2-4% portfolio position on a 5-12% intra-month pullback; attach a stop at -12% and sell 3–6 month covered calls 50–75% OTM to fund carry. Risk/Reward: limited immediate income with 20–30% upside in 12–24 months if spend rebounds; downside is single-digit credit-cycle hit to EPS over one year.
• UNH — Short-duration mean-reversion only: allocate 0.5–1% portfolio to a 6–12 week call-buy (or a long 1–2 month call spread) to capture a technical bounce or guidance clarification. Do not add naked equity exposure until two sequential quarters of normalized MA bids/profitability; downside tail (20–50%) remains elevated if pricing resets worsen.
• EPD — Income-first position: establish a 3–5% portfolio holding and sell 9–12 month covered calls or sell cash-secured puts to increase effective yield (~+200–400bps above spot distribution). Hold 12–24 months to capture distribution + option premium; protect with a 25% drawdown guard since midstream capex/regulatory shocks can produce multi-quarter NAV hits.
• UNH contrarian hedge — Buy a 6–12 month put spread (size 0.5% portfolio) to protect broader healthcare beta against a continuation of MA mispricing or CMS adverse adjustments. Cost is limited; payoff is 3–5x if regulatory/retrospective settlement risks materialize, serving as cheap insurance while avoiding long-term outright short exposure.